Source-grounded facts extracted from Profound Medical Corp.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Profound Medical Corp. shareholders approved Ordinary resolution approving all unallocated restricted share units and deferred share units under the Company's long-term incentive plan at the 2026-05-13 meeting.
“The shareholders approved an ordinary resolution approving all unallocated restricted share units and deferred share units under the Company's long-term incentive plan.”
Profound Medical Corp. shareholders approved Appointment of PricewaterhouseCoopers LLP as auditors of the Company until the close of the next annual meeting at the 2026-05-13 meeting.
“The shareholders approved the appointment of PricewaterhouseCoopers LLP as auditors of the Company until the close of the Company's next annual meeting of shareholders at such remuneration to be fixed by the Board.”
Profound Medical Corp. shareholders approved Election of eight director nominees to serve until the next annual meeting at the 2026-05-13 meeting.
“Each of the eight nominees listed below was elected as director of the Company to hold office until the Company's next annual meeting of shareholders or until their successor is duly appointed.”
Profound Medical Corp. reported the first quarter ended March 31, 2026 results: revenue $5.3 million, net income $7.0 million, EPS $0.19 per common share. Guidance initiated.
“For the quarter ended March 31, 2026, Profound recorded revenue of approximately $5.3 million”
Profound Medical Corp. reported the fourth quarter and full year ended December 31, 2025 results: revenue $6.0 million.
“Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results TORONTO, March 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today reported financial results for the fourth quarter and full year ended December 31, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Q4-2025 revenue grew 43% year-over-year and 13% sequentially quarter-over-quarter to a record $6.0 million.”
Profound Medical Corp. issued 921,428 shares of common stock to certain Canadian investors for $7.00 per share.
“On December 30, 2025, Profound Medical Corp. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with certain Canadian investors (the “Investors”) providing for the private placement of an aggregate of 921,428 shares of the Company’s common shares (the “Shares”), at a per share purchase price of $7.00 (the “Offering”) for aggregate gross proceeds of $6.45 million.”
Profound Medical Corp. entered into Subscription Agreement with certain Canadian investors valued at aggregate gross proceeds of $6.45 million (effective 2025-12-30).
“On December 30, 2025, Profound Medical Corp. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with certain Canadian investors (the “Investors”) providing for the private placement of an aggregate of 921,428 shares of the Company’s common shares (the “Shares”), at a per share purchase price of $7.00 (the “Offering”) for aggregate gross proceeds of $6.45 million.”
Profound Medical Corp. entered into Placement Agent Agreement with Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC valued at cash fee of 5.0% of gross proceeds from the sale of Shares plus reimbursement of documented out-of-p (effective 2025-12-19).
“On December 19, 2025, the Company entered into a placement agency agreement (the “Placement Agent Agreement”) with Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC (“Konik Capital Partners”) pursuant to which the Company engaged Konik Capital Partners as the placement agent (the “Placement Agent”) in connection with the Offering.”
Profound Medical Corp. entered into Securities Purchase Agreement with certain investors (the Purchasers) valued at aggregate of 5,142,870 common shares at $7.00 per share for aggregate gross proceeds of $36 million (effective 2025-12-19).
“On December 19, 2025, Profound Medical Corp. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (collectively, the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a registered direct offering (the “Offering”) an aggregate of 5,142,870 shares (the “Shares”) of the Company’s common shares (the “Common Shares”), at a price of $7.00 per share, for aggregate gross proceeds to the Company of $36 million before deducting the placement agent’s fees and related offering expenses.”
Profound Medical Corp. amended revolving credit of $10,000,000 with Canadian Imperial Bank of Commerce (CIBC) at Wall Street Journal Prime Rate subject to a floor of 6.25% maturing March 3, 2027.
“subject to achieving a minimum trailing 12 month revenue exceeding $15,000,000. The exercise of the option would result in the size of the revolving commitment increasing from $10,000,000 to a maximum of $15,000,000. Additionally, the Credit Agreement provides that the Company may request a one-time increase in the principal amount of the revolving line of credit”
Profound Medical Corp. reported that prior financial statements should not be relied upon.
“On March 6, 2025, the Audit Committee of the Company’s Board of Directors, upon the recommendation of the Company’s management, and after discussion with the Company’s independent registered public accounting firm, PricewaterhouseCoopers LLP, concluded that the Company’s unaudited consolidated financial statements included in the Company’s Reports of Foreign Private Issuer on Form 6-K for the three months ended March 31, 2024, the three and six months ended June 30, 2024 and the three and nine months ended September 30, 2024 filed with the Securities and Exchange Commission (the “SEC”) on May 9, 2024, August 8, 2024 and November 7, 2024, respectively (the “Reports” and all financial statements included in the Reports, collectively, the “Affected Financials”), should no longer be relied upon as a result of the foregoing error.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.